Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
A randomized, double-blind, phase III study in India for ... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
A randomized, double-blind, phase III study in India for comparing efficacy, safety, and PK of ZRC-3277 (pertuzumab biosimilar) with Perjeta® in patients with HER2-positive metastatic breast cancer
0
Authors
Rushabh Kothari
41 more
Rushabh Kothari
•
Ajay Gogia
39 more
•
Deven Parmar
Published
July 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Clinical Breast Cancer
Topics
Medicine
Cancer Oncology
Immunology
Pathology
Internal Medicine
Show all topics
DOI
10.1016/j.clbc.2024.07.001
